These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 20543537)

  • 1. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Goel G; Jauhri M; Negi A; Aggarwal S
    Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
    Di Lauro L; Vici P; Belli F; Tomao S; Fattoruso SI; Arena MG; Pizzuti L; Giannarelli D; Paoletti G; Barba M; Sergi D; Maugeri-Saccà M
    Gastric Cancer; 2014 Oct; 17(4):718-24. PubMed ID: 24318671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
    Anter AH; Abdel-Latif RM
    Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
    Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
    Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
    Van Cutsem E; Boni C; Tabernero J; Massuti B; Middleton G; Dane F; Reichardt P; Pimentel FL; Cohn A; Follana P; Clemens M; Zaniboni A; Moiseyenko V; Harrison M; Richards DA; Prenen H; Pernot S; Ecstein-Fraisse E; Hitier S; Rougier P
    Ann Oncol; 2015 Jan; 26(1):149-156. PubMed ID: 25416687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
    Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma.
    Liu Y; Ye Z; Xi W; Ma T; Shi M; Yang L; Zhu Z; Zhang J
    Biomed Res Int; 2013; 2013():971096. PubMed ID: 24151630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
    Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
    Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
    Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
    Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
    Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P
    Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
    Liu Y; Ma T; Ye ZB; Zhang J; Zhu ZG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Mar; 13(3):177-80. PubMed ID: 20336533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
    Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
    Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
    Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
    Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
    J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
    Giordano KF; Jatoi A; Stella PJ; Foster N; Tschetter LK; Alberts SR; Dakhil SR; Mailliard JA; Flynn PJ; Nikcevich DA;
    Ann Oncol; 2006 Apr; 17(4):652-6. PubMed ID: 16497828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.
    Ramaswamy A; Bhargava P; Dubashi B; Gupta A; Kapoor A; Srinivas S; Shetty O; Jadhav P; Desai V; Noronha V; Joshi A; Menon N; Patil VM; Mishra BK; Sansar B; Singh A; Patel S; Singh SN; Dhal I; Vinayak KR; Pal V; Mandavkar S; Kannan S; Chaugule D; Patil R; Parulekar M; Nashikkar C; Ankathi SK; Kaushal RK; Shah A; Ganesan P; Kayal S; Ananthakrishnan R; Syed N; Samaddar D; Kapu V; Shah A; Kaaviya D; Suganiya R; Srinivasan ND; Prabhash K; Ostwal V
    JNCI Cancer Spectr; 2024 Jul; 8(4):. PubMed ID: 39067037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
    Uronis HE; Bendell JC; Altomare I; Blobe GC; Hsu SD; Morse MA; Pang H; Zafar SY; Conkling P; Favaro J; Arrowood CC; Cushman SM; Meadows KL; Brady JC; Nixon AB; Hurwitz HI
    Oncologist; 2013; 18(3):271-2. PubMed ID: 23485624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.